Binnopharm Group organized a series of scientific events for specialists in gynecology and reproductive health, attended by nearly 400 healthcare professionals. The events were held as part of the 19th All-Russian Scientific and Practical Seminar “Reproductive Potential of Russia: Versions and Controversies.”
The program focused on modern approaches to treating endometriosis and menstrual cycle disorders, as well as the presentation of the capabilities of new drugs in Binnopharm Group’s gynecological portfolio for managing hormone-dependent conditions.
The scientific segment began with a master class led by Professor Vitaly Tskhay, MD, PhD, and his team. Participants were shown clinical aspects of the interdisciplinary approach to treating endometriosis—from diagnosis to surgical interventions and drug therapy.
Professor Tskhay noted that endometriosis remains a socially significant chronic disease and emphasized the importance of introducing an affordable micronized dienogest medication, which expands options for drug treatment of patients in Russia.
The central event of the day was the symposium Hormonal Detective: The Investigation Is Led by Experts, moderated by Academician of the Russian Academy of Sciences, Professor Viktor Radzinsky, MD, PhD. Key national experts in endocrine gynecology participated in the discussion: Professor of the Russian Academy of Sciences, Mariia Yarmolinskaya, Doctor of Sciences in Medicine, and Senior Researcher, Ekaterina Sheremetyeva, Candidate of Sciences in Medicine.
In a “clinical investigation” format, they discussed treatment strategies for menstrual cycle disorders, endometriosis, and the additional benefits of hormonal contraception for women with special needs. The symposium also featured the presentation of Binnopharm Group’s new drug portfolio, which offers physicians additional options for treating hormone-dependent conditions.
The program concluded with a plenary report by Professor Marina Khamoshina, MD, PhD. She presented an overview of the modern role of dydrogesterone in outpatient practice, based on the latest clinical guidelines, and highlighted the significance of domestic generic versions of original drugs for ensuring continuity of therapy and improving treatment accessibility.
“The events generated significant interest among the audience and demonstrated a high level of expert dialogue,” noted Natalya Oliferuk, Head of the Medical Department at Binnopharm Group. “We were listened to by specialists from 80 regions of Russia and physicians from 13 countries around the world. With the launch of our gynecological portfolio, Binnopharm Group faced an important task: to inform physicians about available treatment options. Our priority is not only to be a manufacturer of high-quality medicines but also to engage in educational activities, discuss modern treatments for socially significant diseases with the professional community, and interact openly with physicians who address the problems of thousands of women.”
